Impact of No-Code AI Drug Discovery Platforms on the Operational Cost Structure of Biotechnology Ventures

Citation: Timotej Szalay, "Impact of No-Code AI Drug Discovery Platforms on the Operational Cost Structure of Biotechnology Ventures", Universal Library of Business and Economics, Volume 03, Issue 03.

Copyright: This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Biotechnology ventures face high uncertainty before their programs reach laboratory validation, while early spending decisions shape runway, financing options, and the pace of evidence formation. This review examines how no-code AI drug discovery platforms affect the operating cost structure of early-stage biotechnology ventures. The purpose is to connect in silico discovery workflows with burn-rate planning, time-to-value, and valuation inflection points. The source base contained recent scholarly and industry publications on drug development costs, venture investment, AI-assisted discovery, generative design, multimodal biomedical data, cloud deployment, and no-code drug-discovery tools. The review used comparative source analysis, conceptual synthesis, classification, and analytical generalization. The results identify a cost migration from fixed laboratory commitments toward cloud compute, data work, platform access, model governance, and staged validation. Practical value lies in a management framework that links computational discovery spending to evidence gates, financing decisions, and delayed laboratory buildout.

Keywords: No-Code AI, Drug Discovery, Biotechnology Ventures, Operational Cost Structure, CAPEX, OPEX, In Silico Discovery, Cloud Infrastructure, Burn Rate.

https://doi.org/10.70315/uloap.ulbec.2026.0303001